Last reviewed · How we verify
RC28-E
RC28-E is a monoclonal antibody targeting PD-1.
RC28-E is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | RC28-E |
|---|---|
| Also known as | RC28-E is a chimeric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2. |
| Sponsor | RemeGen Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
RC28-E works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells and thereby enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pneumonitis
Key clinical trials
- Evaluation of RC28-E Injection in Diabetic Macular Edema (PHASE2)
- Evaluation of RC28-E Injection in Diabetic Retinopathy (PHASE2)
- Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema (PHASE3)
- Efficacy and Safety of RC28-E Versus Aflibercept (PHASE3)
- Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration (PHASE1, PHASE2)
- Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RC28-E CI brief — competitive landscape report
- RC28-E updates RSS · CI watch RSS
- RemeGen Co., Ltd. portfolio CI